Page 18 - Read Online

Page 12 of 12 Onea et al. Vessel Plus 2023;7:13 https://dx.doi.org/10.20517/2574-1209.2023.11

19. Kong MG, Han JK, Kang JH, et al; Collaborators. Clinical outcomes of long stenting in the drug-eluting stent era: patient-level pooled
analysis from the GRAND-DES registry. EuroIntervention 2021;16:1318-25. DOI PubMed PMC
20. Lee CH, Kang DY, Han M, et al; IRIS-DES Registry Investigators. Differential cutoff points and clinical impact of stent parameters of
various drug-eluting stents for predicting major adverse clinical events: an individual patient data pooled analysis of seven stent-
specific registries and 17,068 patients. Int J Cardiol 2019;282:17-23. DOI
21. Coughlan JJ, Aytekin A, Koch T, et al. Long-term clinical outcomes after drug eluting stent implantation with and without stent
overlap. Catheter Cardiovasc Interv 2022;99:541-51. DOI PubMed
22. Şaylık F, Çınar T, Selçuk M, Çiçek V, Hayıroğlu MI, Orhan AL. Comparison of outcomes between single long stent and overlapping
stents: a meta-analysis of the literature. Herz 2023. DOI PubMed
23. Mangner N, Farah A, Ohlow MA, et al; BASKET-SMALL 2 Investigators. Safety and efficacy of drug-coated balloons versus drug-
eluting stents in acute coronary syndromes: a prespecified analysis of BASKET-SMALL 2. Circ Cardiovasc Interv 2022;15:e011325.
DOI PubMed
24. Mahfoud F, Farah A, Ohlow MA, et al. Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease:
a pre-specified analysis of the BASKET-SMALL 2 trial. Clin Res Cardiol 2022;111:806-15. DOI PubMed PMC
25. Cortese B, Di Palma G, Guimaraes MG, et al. Drug-coated balloon versus drug-eluting stent for small coronary vessel disease:
PICCOLETO II randomized clinical trial. JACC Cardiovasc Interv 2020;13:2840-9. DOI
26. El-Mokdad R, di Palma G, Cortese B. Long-term follow-up after sirolimus-coated balloon use for coronary artery disease. Final results
of the Nanolutè study. Catheter Cardiovasc Interv 2020;96:E496-500. DOI PubMed
27. Yu X, Wang X, Ji F, et al. A non-inferiority, randomized clinical trial comparing paclitaxel-coated balloon versus new-generation
drug-eluting stents on angiographic outcomes for coronary de novo lesions. Cardiovasc Drugs Ther 2022;36:655-64. DOI PubMed
PMC
28. Uskela S, Kärkkäinen JM, Eränen J, et al. Percutaneous coronary intervention with drug-coated balloon-only strategy in stable
coronary artery disease and in acute coronary syndromes: an all-comers registry study. Catheter Cardiovasc Interv 2019;93:893-900.
DOI PubMed
29. Rosenberg M, Waliszewski M, Chin K, et al. Prospective, large-scale multicenter trial for the use of drug-coated balloons in coronary
lesions: the DCB-only All-Comers registry. Catheter Cardiovasc Interv 2019;93:181-8. DOI PubMed
30. Rosenberg M, Waliszewski M, Krackhardt F, et al. Drug coated balloon-only strategy in de novo lesions of large coronary vessels. J
Interv Cardiol 2019;2019:6548696. DOI PubMed PMC
31. Yamamoto T, Sawada T, Uzu K, Takaya T, Kawai H, Yasaka Y. Possible mechanism of late lumen enlargement after treatment for de
novo coronary lesions with drug-coated balloon. Int J Cardiol 2020;321:30-7. DOI
32. Basavarajaiah S, Latib A, Shannon J, et al. Drug-eluting balloon in the treatment of in-stent restenosis and diffuse coronary artery
disease: real-world experience from our registry. J Interv Cardiol 2014;27:348-55. DOI
33. Basavarajaiah S, Athukorala S, Kalogeras K, et al. Mid-term clinical outcomes from use of Sirolimus coated balloon in coronary
intervention; data from real world population. Catheter Cardiovasc Interv 2021;98:57-65. DOI PubMed
34. Ielasi A, Miyazaki T, Geraci S, et al. Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary
artery disease: the “no more metallic cages” multicentre pilot experience. EuroIntervention 2016;11:e1589-95. DOI PubMed
35. Merinopoulos I, Gunawardena T, Wickramarachchi U, et al. Long-term safety of paclitaxel drug-coated balloon-only angioplasty for
de novo coronary artery disease: the SPARTAN DCB study. Clin Res Cardiol 2021;110:220-7. DOI PubMed PMC
36. Yang YX, He KZ, Li JY, et al. Comparisons of drug-eluting balloon versus drug-eluting stent in the treatment of young patients with
acute myocardial infarction. J Cardiovasc Dev Dis 2023;10:29. DOI PubMed PMC
37. Wickramarachchi U, Corballis NH, Maart CA, Gilbert TJ, Eccleshall SC, et al. 24 drug coated balloon-only angioplasty in chronic
total occlusions, a UK single centre experience. Heart 2017;103:A11. Available from: https://heart.bmj.com/content/103/Suppl_7/A11.1 .
[Last accessed on 10 Jul 2023]
38. Köln PJ, Scheller B, Liew HB, et al. Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without
stenting - a feasibility and safety study. Int J Cardiol 2016;225:262-7. DOI
39. Jun EJ, Shin ES, Teoh EV, et al. Clinical outcomes of drug-coated balloon treatment after successful revascularization of de novo
chronic total occlusions. Front Cardiovasc Med 2022;9:821380. DOI PubMed PMC
40. Pan L, Lu W, Han Z, et al. Clinical outcomes of drug-coated balloon in coronary patients with and without diabetes mellitus: a
multicenter, propensity score study. J Diabetes Res 2021;2021:5495219. DOI PubMed PMC
41. Ielasi A, Buono A, Pellicano M, et al. A hybrid approach evaluating a drug-coated balloon in combination with a new-generation drug-
eluting stent in the treatment of de novo diffuse coronary artery disease: the HYPER pilot study. Cardiovasc Revasc Med 2021;28:14-
9. DOI PubMed
42. Yang X, Lu W, Pan L, et al. Long-term outcomes of drug-coated balloons in patients with diffuse coronary lesions. Front Cardiovasc
Med 2022;9:935263. DOI PubMed PMC
43. Shin ES, Jun EJ, Kim S, et al. Clinical impact of drug-coated balloon-based percutaneous coronary intervention in patients with
multivessel coronary artery disease. JACC Cardiovasc Interv 2023;16:292-9. DOI PubMed
44. Corrigendum to: paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a
comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J
2020;41:3728. DOI PubMed PMC
45. Cortese B, Erriquez A, Alfonso F. Reply: seeking an appropriate primary endpoint for trials comparing DCB and DES. JACC
Cardiovasc Interv 2021;14:710-1. DOI PubMed